EcoDrugPlus

Amine Oxidase Copper Containing 3

Ensembl ID : ENSECRG00000019916
Gene Symbol: AOC3
3 Cross references
413 Possible Orthologues:

Amylase Alpha 1c

Ensembl ID : ENSECRG00000013223
Gene Symbol: AMY1C
3 Cross references
207 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSECRG00000022773
Gene Symbol: APP
3 Cross references
279 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSECRG00000009512
Gene Symbol: AR
3 Cross references
277 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSECRG00000015345
Gene Symbol: AGTR1
1 Cross references
214 Possible Orthologues:

Angiotensin Ii Receptor, Type 2

Ensembl ID : ENSECRG00000014762
Gene Symbol: AGTR2
1 Cross references
192 Possible Orthologues:

Angiotensin Ii Receptor, Type 2

Ensembl ID : ENSECRG00000014383
Gene Symbol: AGTR2
1 Cross references
192 Possible Orthologues:

Angiotensin Ii Receptor, Type 2

Ensembl ID : ENSECRG00000010745
Gene Symbol: AGTR2
1 Cross references
192 Possible Orthologues:

Anti-Apoptotic Protein Nr13-Like

Ensembl ID : ENSECRG00000018107
Gene Symbol: LOC114667502
3 Cross references
129 Possible Orthologues:

Apelin Receptor

Ensembl ID : ENSECRG00000009293
Gene Symbol: APLNR
3 Cross references
172 Possible Orthologues:

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSECRG00000008960
Gene Symbol: APH1A
3 Cross references
130 Possible Orthologues:

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSECRG00000017681
Gene Symbol: APH1A
2 Cross references
130 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).